Sökning: id:"swepub:oai:lup.lub.lu.se:607a8f39-e29b-41d5-aeb5-a6a93ba9028a" >
Small cells – big i...
Small cells – big issues : biological implications and preclinical advancements in small cell lung cancer
-
- Solta, Anna (författare)
- Medical University of Vienna
-
- Ernhofer, Büsra (författare)
- Medical University of Vienna
-
- Boettiger, Kristiina (författare)
- Medical University of Vienna
-
visa fler...
-
- Megyesfalvi, Zsolt (författare)
- National Korányi Institute for Tuberculosis and Pulmonology, Hungary,Medical University of Vienna,National Institute of Oncology, Budapest
-
- Heeke, Simon (författare)
- University of Texas
-
- Hoda, Mir Alireza (författare)
- Medical University of Vienna
-
- Lang, Christian (författare)
- Medical University of Vienna
-
- Aigner, Clemens (författare)
- Medical University of Vienna
-
- Hirsch, Fred R. (författare)
- Icahn School of Medicine at Mount Sinai,University of Colorado School of Medicine
-
- Schelch, Karin (författare)
- Medical University of Vienna
-
- Döme, Balazs (författare)
- Lund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Clinical Chemistry, Malmö,Lund University Research Groups,National Korányi Institute for Tuberculosis and Pulmonology, Hungary,Medical University of Vienna,National Institute of Oncology, Budapest
-
visa färre...
-
(creator_code:org_t)
- 2024
- 2024
- Engelska.
-
Ingår i: Molecular Cancer. - 1476-4598. ; 23:1
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Current treatment guidelines refer to small cell lung cancer (SCLC), one of the deadliest human malignancies, as a homogeneous disease. Accordingly, SCLC therapy comprises chemoradiation with or without immunotherapy. Meanwhile, recent studies have made significant advances in subclassifying SCLC based on the elevated expression of the transcription factors ASCL1, NEUROD1, and POU2F3, as well as on certain inflammatory characteristics. The role of the transcription regulator YAP1 in defining a unique SCLC subset remains to be established. Although preclinical analyses have described numerous subtype-specific characteristics and vulnerabilities, the so far non-existing clinical subtype distinction may be a contributor to negative clinical trial outcomes. This comprehensive review aims to provide a framework for the development of novel personalized therapeutic approaches by compiling the most recent discoveries achieved by preclinical SCLC research. We highlight the challenges faced due to limited access to patient material as well as the advances accomplished by implementing state-of-the-art models and methodologies.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Molecular subtypes
- Preclinical models
- Small cell lung cancer
- Translational progress
Publikations- och innehållstyp
- for (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Solta, Anna
-
Ernhofer, Büsra
-
Boettiger, Krist ...
-
Megyesfalvi, Zso ...
-
Heeke, Simon
-
Hoda, Mir Alirez ...
-
visa fler...
-
Lang, Christian
-
Aigner, Clemens
-
Hirsch, Fred R.
-
Schelch, Karin
-
Döme, Balazs
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Molecular Cancer
- Av lärosätet
-
Lunds universitet